Table 5.
Late adverse effects at 3 years after tandem HDCT/auto-SCT
| NB-2004 (n = 32) |
NB-2009 (n = 27) |
P value | |
|---|---|---|---|
| Endocrinopathy | |||
| Hypothyroidism, n (%) | 12 (37.5) | 11 (40.7) | 0.799 |
| Growth hormone deficiency, n (%) | 9 (28.1) | 1 (3.7) | 0.016 |
| Glucocorticoid deficiency, n (%) | 1 (3.1) | 0 (0.0) | 0.542 |
| Sex hormone deficiency, n (%) | 1/2a (50.0) | 1/3a (33.3) | 0.700 |
| Height, Z-score, median (range) | −1.46 (−5.66–0.93) | −0.65 (−2.78–1.40) | 0.004 |
| Weight, Z-score, median (range) | −0.84 (−2.91–0.75) | −0.32 (−2.15–2.08) | 0.014 |
| BMI, Z-score, median (range) | −0.38 (−2.58–1.62) | −0.42 (−1.86–2.68) | 0.166 |
| Hearing loss, n (%) | 24 (75.0) | 16 (59.3) | 0.197 |
| Cataract, n (%) | 9 (28.1) | 0 (0) | 0.002 |
| Chronic lung disease, n (%) | 2 (6.3) | 0 (0.0) | 0.673 |
| Renal | |||
| Glomerulopathy, n (%) | 18 (56.3) | 4 (14.8) | 0.001 |
| Tubulopathy, n (%) | 20 (62.5) | 17 (63.0) | 0.971 |
| Cardiac dysfunction, n (%) | 0 (0.0) | 0 (0.0) | 1.000 |
| Presence of grade 3 dysfunction, n (%) | 4 (12.5) | 2 (7.4) | 0.678 |
| Number of dysfunctions/patient, median (range) | 3 (0–7) | 2 (0–4) | 0.003 |
BMI body mass index
aOnly adolescents were analyzed